
Ya PHARMACOSERÍAS había denunciado el tema...Seguro nos leyeron y se lo "copiaron"
Ahora el informe dice:
As in banking, pay and executive remuneration packages have now reached excessive levels in the pharmaceutical industry. As table shows, despite apparent declining rates of innovation the top pharmaceutical executives are awarding themselves huge financial rewards.
In February 2009 Alistair Darling promised to launch a probe into excessive remuneration packages in the City– this investigation must be extended to the pharmaceutical industry. Controlling pay and bonuses is essential so that executive rewards and share options do not disfigure the product market as they did in financial services.
Y aporta estos datos:

Ver anteriores...te interesará

No hay comentarios:
Publicar un comentario